1 BTC
=
- USD
BIOMERICA INC
As of May 30, 2026 at 24:05 UTC
Chart
About BIOMERICA INC
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
Market Statistics
Trading Metrics
How to Buy BMRA
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy BMRA
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesBiomerica reported Q2 FY2026 results with net sales of $1.21M (down from $1.64M YoY) as the company transitions from legacy products to higher-margin diagnostic offerings. Key developments include a partnership with Henry Schein for inFoods® IBS commercialization, launch of an AI-backed Trigger Food Navigator tool, CMS establishment of a $300 Medicare reimbursement rate for inFoods® IBS, and Egyptian Drug Authority approval of the company's screening test portfolio. Operating expenses declined 4% YoY to $2.96M for the six-month period, and working capital improved by 14.7%.
Biomerica reported modest financial performance with $5.3 million in net sales, reduced operating expenses by $1.3 million, and improved operating loss by 19%. The company focused on strategic growth in diagnostic tests, particularly inFoods® IBS, and expanded international market presence.
Biomerica reported a modest 1% increase in total revenue for fiscal year 2024, with a 5% increase in core revenue excluding COVID-19 tests. The company implemented a significant cost-savings plan and reduced its net loss by 15%. Key milestones included FDA clearance for its Hp Detect Stool Antigen ELISA test and progress in the inFoods IBS pilot program.
IRVINE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, is proud to announce a major enhancement to its inFoods® IBS system, aimed at simplifying and transforming the patient experience.